If this is a forwarded email, subscribe now to receive future updates on this topic. |
|---|
You are subscribed to one or more CDC code set email subscription services. Subscription links are available on each of the pages below. Vaccine Code Set Update Publication Date: November 07, 2023
The individual filenames included in this distribution contain the publication date (20231107) Release Notes: This release includes updates for all vaccine codes and maps but does not include codes for Vaccine Information Statements (VIS). General note regarding this release: Codes with “Last Update” dates after September 20, 2023, and before November 06, 2023, reflect the changes and additions in this release. This release includes the following code set updates: - New pentavalent meningococcal vaccine (PENBRAYA) CVX and product codes
- New anthrax vaccine (CYFENDUS) NDC and product codes for Strategic National Stockpile use
- Retirement of U.S. COVID-19 CVX and NDC codes for the vaccine formulations used prior to Fall 2023
Vaccine Code Set Updates – Details - New pentavalent meningococcal vaccine (PENBRAYA) CVX and product codes
A new Meningococcal Groups A, B, C, W, and Y vaccine (PENBRAYA) will be available in January 2023. In anticipation, a new CVX code, Product/Tradename record and product association to Pfizer MVX are included in this code set release. NDC and CPT codes are not yet available.
New CVX code 316 shown below is associated to two Vaccine Groups “MENING” and “MeningB”.
A new Product table entry has also been added for PENBRAYA and associated to the Pfizer MVX code “PFR”.
CVX Code | CVX Short Description | Full Vaccine Name | Note | Vaccine Status |
|---|
316 | meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free | Meningococcal pentavalent vaccine strains ABCW and Y | Active |
|---|
- New anthrax vaccine (CYFENDUS) NDC and product codes for Strategic National Stockpile use
A new anthrax vaccine has been added to the code sets. This vaccine is labeled for Strategic National Stockpile use only. The existing CVX code for anthrax has been associated to this new product. A new Product table entry has also been added for CYFENDUS. The Note field for MVX code MIP “Emergent BioSolutions” has been updated to reflect the addition of the below sale labeler name under the existing MVX code.
CVX Code | CVX Description | MVX Code | Sale Proprietary Name | Sale NDC11 | Use NDC11 | Sale Labeler |
|---|
24 | anthrax | MIP | CYFENDUS | 71665-0001-02 | 71665-0001-01 | Emergent Product Development Gaithersburg Inc. |
|---|
- Retirement of U.S. COVID-19 CVX and NDC codes for the vaccine formulations used prior to Fall 2023
All active CVX and NDC codes for COVID-19 vaccines authorized prior to the Fall 2023 new COVID-19 vaccines have now been retired. The CVX code Vaccine Status has been set to “Inactive”, the NDCs associated to that CVX code have had the NDC end date set based on the FDA authorization rescission date or the date the product was no longer available or was expired. The inactive CVX codes may continue to be utilized to record historic vaccine administrations in the U.S. or, as applicable, may be used to record historic vaccines administered in other countries. No changes have been made to the Non-U.S. COVID-19 CVX codes. Updates to the COVID-19 codes web pages are planned in the near future to better reflect these changes and to remove content that is no longer relevant. The Note field for each retired CVX code has also been updated to reflect these changes.
Current COVID-19 vaccine codes may be found at IIS Data Code Sets | CDC
The table below identifies the CVX codes and related NDC codes that are now retired.
CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | NDC End Date |
|---|
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Spikevax | Moderna US, Inc. | 80777-0100-99 | 80777-0100-11 | 4/18/2023 |
|---|
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0273-98 | 80777-0273-15 | 4/18/2023 |
|---|
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0273-99 | 80777-0273-10 | 4/18/2023 |
|---|
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1000-02 | 59267-1000-01 | 4/18/2023 |
|---|
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1000-03 | 59267-1000-01 | 4/18/2023 |
|---|
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 80631-0100-10 | 80631-0100-01 | 10/3/2023 |
|---|
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 80631-0102-10 | 80631-0102-01 | 10/3/2023 |
|---|
212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | Janssen COVID-19 Vaccine | Janssen Products, LP | 59676-0580-15 | 59676-0580-05 | 6/20/2023 |
|---|
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 00069-2025-25 | 00069-2025-01 | 9/11/2023 |
|---|
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 00069-2025-10 | 00069-2025-01 | 9/11/2023 |
|---|
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1025-02 | 59267-1025-01 | 11/1/2021 |
|---|
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1025-03 | 59267-1025-01 | 4/18/2023 |
|---|
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1025-04 | 59267-1025-01 | 4/18/2023 |
|---|
218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1055-04 | 59267-1055-01 | 4/18/2023 |
|---|
218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-1055-02 | 59267-1055-01 | 11/1/2021 |
|---|
219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-0078-04 | 59267-0078-01 | 4/18/2023 |
|---|
221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0275-99 | 80777-0275-05 | 4/18/2023 |
|---|
227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0277-99 | 80777-0277-05 | 6/1/2022 |
|---|
228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0279-99 | 80777-0279-05 | 4/18/2023 |
|---|
229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 80777-0282-99 | 80777-0282-05 | 9/11/2023 |
|---|
230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 80777-0283-99 | 80777-0283-02 | 9/11/2023 |
|---|
300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 59267-0304-02 | 59267-0304-01 | 9/11/2023 |
|---|
300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 59267-1404-02 | 59267-1404-01 | 9/11/2023 |
|---|
301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 59267-0565-02 | 59267-0565-01 | 9/11/2023 |
|---|
302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 59267-0609-02 | 59267-0609-01 | 9/11/2023 |
|---|
|
|---|
Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348
Questions or Problems | |
|---|
|
|---|
|
